| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127,1 M € | +10.5% | 115,0 M € | +14.7% | 100,3 M € | -0.4% | 100,7 M € | +5.5% | 95,5 M € | +3.6% | 92,2 M € | +16.6% | 79,1 M € | -0.9% | 79,8 M € | +17.3% | 68,1 M € | +52.5% | 44,6 M € | +10.4% | 40,4 M € | +40.8% | 28,7 M € | +7.9% | 26,6 M € | +8.5% | 24,5 M € | +15.6% | 21,2 M € | +36.1% | 15,6 M € | -1.3% | 15,8 M € | -14.6% | 18,5 M € | |
| EBITDA | 21,5 M € | +13.7% | 18,9 M € | +6.1% | 17,8 M € | +0.2% | 17,8 M € | +1.9% | 17,5 M € | +10.2% | 15,8 M € | +7.8% | 14,7 M € | +13.7% | 12,9 M € | +33.1% | 9,7 M € | +98.3% | 4,9 M € | +41.8% | 3,5 M € | +129.1% | 1,5 M € | +4.6% | 1,4 M € | +8.3% | 1,3 M € | +34.0% | 992,5 k € | +1671.4% | -63,2 k € | +94.1% | -1,1 M € | +25.8% | -1,4 M € | |
| Operating profit | 8,4 M € | +23.2% | 6,8 M € | +8.7% | 6,3 M € | -2.2% | 6,4 M € | -1.4% | 6,5 M € | +13.4% | 5,8 M € | +11.6% | 5,2 M € | -3.3% | 5,3 M € | +23.7% | 4,3 M € | +60.0% | 2,7 M € | -2.5% | 2,8 M € | +90.1% | 1,5 M € | +6.3% | 1,4 M € | +6.7% | 1,3 M € | +42.3% | 902,9 k € | +874.9% | -116,5 k € | +89.4% | -1,1 M € | +24.5% | -1,5 M € | |
| Profit/loss | 5,9 M € | +23.3% | 4,8 M € | +11.4% | 4,3 M € | -1.2% | 4,3 M € | -8.6% | 4,8 M € | +11.8% | 4,2 M € | +22.1% | 3,5 M € | +10.7% | 3,1 M € | +9.1% | 2,9 M € | +114.5% | 1,3 M € | -25.4% | 1,8 M € | +95.1% | 922,7 k € | -19.2% | 1,1 M € | -14.2% | 1,3 M € | +73.3% | 767,8 k € | +992.8% | 70,3 k € | +104.5% | -1,6 M € | +5.5% | -1,6 M € | |
| Equity | 49,8 M € | +13.4% | 43,9 M € | +12.2% | 39,1 M € | +12.3% | 34,8 M € | +14.2% | 30,5 M € | +18.5% | 25,7 M € | +19.8% | 21,5 M € | +19.3% | 18,0 M € | +21.2% | 14,9 M € | +53.3% | 9,7 M € | +16.1% | 8,4 M € | +51.1% | 5,5 M € | +20.0% | 4,6 M € | +33.0% | 3,5 M € | +62.4% | 2,1 M € | +56.3% | 1,4 M € | +5.4% | 1,3 M € | -54.6% | 2,9 M € | |
| Total assets | 107,7 M € | +10.4% | 97,5 M € | +18.0% | 82,7 M € | +1.9% | 81,1 M € | +2.0% | 79,5 M € | +2.0% | 78,0 M € | +10.3% | 70,7 M € | +9.3% | 64,7 M € | +4.2% | 62,1 M € | +59.7% | 38,9 M € | +22.1% | 31,8 M € | +102.5% | 15,7 M € | +28.8% | 12,2 M € | +15.1% | 10,6 M € | -5.5% | 11,2 M € | +30.9% | 8,6 M € | -18.3% | 10,5 M € | +38.7% | 7,6 M € | |
| Cash | 4,6 M € | -20.8% | 5,8 M € | +33.1% | 4,4 M € | -6.4% | 4,7 M € | +19.7% | 3,9 M € | +40.2% | 2,8 M € | +76.6% | 1,6 M € | +6.1% | 1,5 M € | +5.7% | 1,4 M € | -47.8% | 2,7 M € | +30.7% | 2,1 M € | +217.6% | 646,8 k € | +132.2% | 278,6 k € | -43.9% | 496,6 k € | +33.2% | 372,9 k € | +35.7% | 274,8 k € | -28.6% | 385,1 k € | +38.4% | 278,3 k € | |
| Debts | 50,5 M € | +4.8% | 48,2 M € | +26.5% | 38,1 M € | -7.7% | 41,3 M € | -9.3% | 45,6 M € | -6.2% | 48,6 M € | +7.5% | 45,2 M € | +4.4% | 43,3 M € | -2.8% | 44,5 M € | +69.2% | 26,3 M € | +27.5% | 20,6 M € | +140.9% | 8,6 M € | +31.2% | 6,5 M € | +4.6% | 6,2 M € | -26.3% | 8,5 M € | +32.7% | 6,4 M € | -27.0% | 8,7 M € | +96.7% | 4,4 M € | |
| Staff | 102,2 | 82 | 81 | 79,3 | 76,1 | 71,9 | 64,4 | 53,2 | 54,8 | 39,7 | 53 | 41,2 | 35,2 | 27,4 | 24,3 | 22,8 | 17,6 | 10,9 | ||||||||||||||||||
Public limited company · Antwerpen · incorporated on 27/07/2005 · 102,2 ETP
Public limited company profitable and well capitalised. Cash position declining (-20.8%).
Solid counterparty for a standard engagement.
HuVePharma is a Public limited company incorporated in 2005. Its main activity is: Wholesale of grain, unmanufactured tobacco, seeds and animal feeds. Its registered office is in Antwerpen. It employs on average 102,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette